Navigation Links
Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
Date:6/8/2009

Analysis of Subjects with Moderately Severe Diabetic Neuropathy Shows Statistically Significant Improvement in Multiple Quantitative Neurological Endpoints

RICHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of as yet unreleased positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA), held in New Orleans, LA, from June 5 to 9, 2009. Data from Sangamo's SB-509-601 and SB-509-701A Phase 2 clinical trials demonstrated that SB-509 treatment resulted in statistically significant and clinically relevant improvements in subjects with moderate and severe DN as compared to placebo. SB-509 was well-tolerated in both multi-dose studies.

"We have learned a great deal from these data, which demonstrate positive activity of SB-509 in multiple clinically relevant measurements of nerve health," stated Dale Ando, M.D., Sangamo's Vice President of Therapeutic Development and Chief Medical Officer. "Data from our Phase 1 and both Phase 2 clinical trials have shown us that the dual angiogenic and neurotrophic effects of SB-509 are most effective in the later stages of DN when both diabetic microvascular disease and metabolic neuropathy are evident. The statistically significant improvement in SB-509-treated subjects across multiple independent clinical endpoints for DN has enabled definition of a responder group and is particularly encouraging for future trials in this patient population."

"SB-509 is the first drug candidate of its type designed to harness the body's own regenerative potential to address DN, a significant complication for diabetic patients," stated Alan Lewis, Ph.D., President and Chief
'/>"/>

SOURCE Sangamo
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
2. Sangamo BioSciences Reports First Quarter 2009 Financial Results
3. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. BD Biosciences Launches New Cell Analyzer for Complex Multicolor Experiments in Disease and Drug Development Research
6. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
8. Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
9. Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
10. Pressure BioSciences, Inc. Provides Corporate Update
11. BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... By Dennis Thompson ... -- The first confirmed case of Ebola has surfaced in ... from Liberia, federal health officials announced late Tuesday. The ... Hospital in Dallas, has been diagnosed with the deadly ... Prevention said in a late afternoon news conference. The ...
(Date:9/30/2014)... Health Day Reporter TUESDAY, ... who are overweight or obese when diagnosed appear to ... weight-related cancer, new research suggests. , , The finding ... only the potential for developing other cancers associated with ... who reported being overweight or obese prior to diagnosis ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling costs ... treat Medicare patients has had no meaningful impact on ... in the Journal of Clinical Oncology published ... chemotherapy to treat colorectal and lung cancers, and did ... those drugs following the implementation of the recent Medicare ...
(Date:9/30/2014)... 30, 2014 Research by UC Irvine immunologists reveals ... light on a vital process that determines how the ... online version of Nature Immunology , neurology professor ... Institute for Immunology colleagues describe a critical mechanism underlying ... the bloodstream. , A T cell is a type ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 Fat ... nutrition specialist and best-selling author Mike Geary that is helping ... transform their body into a fat-burning machine in less than ... an investigative review. , “In our culture that is ... be hard to decipher what is really fact and fiction ...
Breaking Medicine News(10 mins):Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 2Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:UCI study uncovers important process for immune system development 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3
... diseases and treatments, experts say , FRIDAY, Oct. 16 ... map of the human epigenome, gaining greater understanding of ... we,ve been limited to viewing small snippets of the ... Analysis Laboratory at the Salk Institute for Biological Studies ...
... 16 When Royal Caribbean International officially names Oasis ... revolutionary cruise ship - on Nov. 30, 2009 from Port ... line will be doing more than making wishes come true ... the country through the Make-A-Wish Foundation. Royal Caribbean will be ...
... increasing the overall death rate in the German population. Matthias ... Sciences of the University of Hamburg and his co-authors present ... Deutsches rtzeblatt International ( Dtsch Artzebl Int 2009; ... index (BMI) between 25 and 29.9 kg/m2. About 20% are ...
... ... the nation,s first association for providers of private pay home care, has announced that a state ... ... association for providers of private pay home care, has announced that a state chapter has been ...
... work can stave off disease and decline, study finds, ... to a healthier retirement may be surprising: work. , ... part-time, are less likely to experience physical decline and ... the national Health and Retirement Study, researchers analyzed six ...
... Deborah Friberg, Chief Operating Officer and Executive Vice ... has been named the recipient of the first annual ... presented by the Association for Professionals in Infection Control ... executive team member who has demonstrated significant support for ...
Cached Medicine News:Health News:Scientists Provide First Map of Complete Human Epigenome 2Health News:Royal Caribbean to Grant Wishes Onboard Oasis Of The Seas 2Health News:Royal Caribbean to Grant Wishes Onboard Oasis Of The Seas 3Health News:Royal Caribbean to Grant Wishes Onboard Oasis Of The Seas 4Health News:National Private Duty Association Announces Formation of an Iowa Chapter 2Health News:For a Healthier Retirement, Work a Little 2Health News:For a Healthier Retirement, Work a Little 3Health News:APIC Announces Winner of First Healthcare Administrator Award 2Health News:APIC Announces Winner of First Healthcare Administrator Award 3
(Date:9/30/2014)... -- Wrightington, Wigan and Leigh NHS ... ) are delighted to announce WWL,s decision to implement ... system. The system will be implemented across all three ... delivers healthcare in the future. WWL ... and on-budget system implementations as well as its proven ...
(Date:9/30/2014)... 2014 This study provides an analysis ... solutions including nuclear imaging informatics, PET imaging informatics, ... assesses the size of the market based on ... projects future growth based on the current drivers ... place in the broader markets for imaging equipment, ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources ... devices in Brazil , ... China (BRIC) will see robust ... are increasingly favored over surgical procedures. Although revenues will ... resources, reimbursement challenges, prolonged device approval times and demand ...
Breaking Medicine Technology:Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3
... Australia, Sept. 26 Hospira, Inc. (NYSE: ... injectable pharmaceuticals, today announced that it has received ... biosimilar filgrastim product, Nivestim™. Nivestim ... including the prevention of febrile neutropenia (FN) and ...
... Pharma US, Inc. ("Astellas") announced results of a ... comparable to placebo in causing a >15% decrease ... in subjects with asthma or chronic obstructive pulmonary ... perfusion imaging (MPI) studies(1). Results were presented during ...
Cached Medicine Technology:Hospira Receives TGA Approval for Nivestim™, Australia's First Biosimilar Filgrastim 2Hospira Receives TGA Approval for Nivestim™, Australia's First Biosimilar Filgrastim 3Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 2Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 3Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 4Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 5
... spectrophotometer designed specifically to run 24 hours ... rugged hardware, proven optical performance and a ... traditional spectrophotometry to obtain results quickly, accurately ... up to eight, 1 cm Biocell cuvettes ...
The PerkinElmer LS 45 Luminescence spectrometer offers versatility, reliability and ease-of-use for routine analyses in an affordable package....
... a new generation Spectrophotometer for near ... nm to 1020 nm with built-in ... and printer. It features four digit ... transmittance, absorption and concentration with excellent ...
... UV/visible spectrophotometers provide ease-of-use and proven technology ... DU Series 800 high-performance spectrophotometers with microfocused ... as small as 5 l. The DU ... intended for use in quantitative and qualitative ...
Medicine Products: